Holen Sie sich die Stockscreener-App
2.83
2.91%
0.08
Handel nachbörslich:
2.83
Schlusskurs vom Vortag:
$2.75
Offen:
$2.75
24-Stunden-Volumen:
7.22M
Relative Volume:
0.82
Marktkapitalisierung:
$2.50B
Einnahmen:
$1.31M
Nettoeinkommen (Verlust:
$-597.65M
KGV:
-2.9175
EPS:
-0.97
Netto-Cashflow:
$-425.62M
1W Leistung:
-1.39%
1M Leistung:
-0.35%
6M Leistung:
-3.74%
1J Leistung:
-53.83%
1-Tages-Spanne:
$2.74
$2.87
1-Wochen-Bereich:
$2.70
$2.95
52-Wochen-Spanne:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Vergleichen Sie IBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.83 | 2.53B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | BTIG Research | Buy |
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha
ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks
ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks
ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks
Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN
ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener
UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard
ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global Oncology Leadership - AInvest
Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication - MarketScreener
ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success - Insider Monkey
ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA - Yahoo Finance
Anktiva Approved For Additional Treatment - Los Angeles Business Journal
ImmunityBio Approves 2025 Equity Incentive Plan - TipRanks
ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360
ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News
ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN
15 Stocks That Stole The Show Last Week - Insider Monkey
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today - Yahoo Finance
H.C. Wainwright maintains buy rating on ImmunityBio stock after FDA milestones - Investing.com Nigeria
ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwr - GuruFocus
ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwright | IBRX Stock News - GuruFocus
Cancer Treatment Granted Lymphopenia Indication - Vax-Before-Travel
Video: ImmunityBio Stock Soars 8.30% on ASCO 2025 Breakthrough! - AInvest
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield - Yahoo Finance
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer - Bakersfield.com
ImmunityBio (IBRX) Receives Maintained Buy Rating from D. Boral Capital | IBRX Stock News - GuruFocus
FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia - Yahoo
FDA authorizes ANKTIVA for lymphopenia in cancer patients By Investing.com - Investing.com South Africa
ImmunityBio (IBRX) Gains FDA Nod for Cancer BioShield Platform - GuruFocus
ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva - Seeking Alpha
ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients - marketscreener.com
Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors - marketscreener.com
ImmunityBio (IBRX) Gains FDA Approval for Expanded Access to Can - GuruFocus
FDA authorizes ANKTIVA for lymphopenia in cancer patients - Investing.com Australia
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Placera.se
Immunitybio Receives FDA Expanded Access Authorization For Landmark Treatment Of Lymphopenia With Anktiva - marketscreener.com
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA - Business Wire
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, - openPR.com
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio - The Globe and Mail
ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates - TradingView
ImmunityBio: Analyst Reaffirms $30 Price Target and Other Important Updates - TradingView
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):